TIM S.A. — Form 6-K Summary
Reporting context: The filing reports minutes of TIM S.A.’s Board of Directors meeting held on December 15, 2021. Although the request identifies December 31, 2021, the source document does not report financial results for that period.
Key financial and operating matters
- The Board approved a distribution of R$560.0 million in Interest on Shareholders’ Equity (JSCP), equal to R$0.231366129 gross per share.
- The shareholder record date is December 20, 2021; shares acquired after that date trade without entitlement to the distribution. Payment was scheduled by January 25, 2022.
- A 15% income-tax withholding applies at credit, subject to differentiated taxation or exemptions.
- The Board acknowledged and approved the company’s budget guidelines for 2022 following management’s presentation of the 2022–2024 Industrial Plan.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance metrics.
Material changes and corporate actions
- Carlo Nardello resigned, effective immediately, from the Board and from the Compensation and Environmental, Social & Governance committees.
- Claudio Giovanni Ezio Ongaro was appointed to the Board, subject to ratification at the next Annual and Extraordinary Shareholders’ Meeting, and was also appointed to both committees.
- The Board approved the Compensation Policy, Nomination Policy, and evaluation process for the Board, advisory committees, and executive officers to address Novo Mercado governance requirements.
- The Board elected an eight-member executive team for a two-year term, including Pietro Labriola as Chief Executive Officer and Camille Loyo Faria as Chief Financial Officer and Investor Relations Officer.
Outlook, strategic projects, and risks
- Management presented the 2022–2024 Industrial Plan and the Board approved budget guidelines for 2022; the filing does not disclose quantitative guidance or targets.
- The company is studying a strategic project involving platforms for offering healthcare services to customers. Management was authorized to conduct additional internal studies, hire external consultants, and take preliminary implementation steps. No final approval, investment amount, timing, or expected financial impact was disclosed.
- The Board acknowledged ongoing compliance work related to Novo Mercado obligations, including governance evaluations and management policies.
- The filing contains no specific discussion of litigation, contingencies, debt maturities, liquidity risks, or other unusual financial items.
Investor verification points
- Confirm the final 2021 financial statements and determine whether the requested December 31, 2021 reporting period is covered by a separate filing.
- Verify payment of the R$560.0 million JSCP distribution, applicable withholding, and the entitlement date.
- Review the full 2022–2024 Industrial Plan and 2022 budget for quantitative targets, capital expenditures, and cash-flow implications.
- Monitor the healthcare-platform project for Board approval, transaction terms, funding requirements, and execution risks.
- Confirm shareholder ratification of Claudio Giovanni Ezio Ongaro’s appointment and subsequent changes to Board or executive composition.